A Slight Decrease in the Serum Albumin Level is Associated with the Rapid Progression of Kidney Dysfunction, Even within the Normal Range

Hoichi Amano1,4, Kazunobu Yoshimura2, Ryutaro Iijima2, Kaito Waki1, Keisei Matsumoto3, Hitomi Ueda2, Yasuko Ito2, Kimihiko Akimoto1, Takashi Yokoo4, Kazuo Inoue5 and Hiroyuki Terawaki2

Abstract:
Objective A low-normal albumin level is associated with a high risk of cardiovascular disease and mortality in the general population. However, the relationship between the serum albumin level and the future decline in the kidney function is unclear. We evaluated the effect of the serum albumin level on the decline in the kidney function in the general population.

Methods The data used were from 11,000 participants in a voluntary health checkup program conducted between 1998 and 2006 in Japan. The primary outcome for the kidney function was a difference in the estimated glomerular filtration rate (ΔeGFR) of ≥3 mL/min/1.73 m²/year. The association of the risk of a decreased kidney function with the albumin level was determined using a logistic regression analysis. We fit separate multivariable logistic regressions for the serum albumin levels (g/dL) as a continuous variable and as categorical data, classified as ≤4.3 (n=2,530), 4.4-4.6 (n=5,427), and ≥4.7 (n=3,043).

Results Of the 11,000 participants, 346 had a ΔeGFR/year of ≥3. Compared with the participants with albumin levels of ≥4.7 g/dL, the risk of a decline in the kidney function was higher not only in those with albumin levels of ≤4.3 g/dL [adjusted odds ratio (OR)=2.10, 95% confidence interval (CI): 1.20-2.93] but also in those with levels of 4.4-4.6 g/dL (adjusted OR=1.53, 95% CI: 1.14-2.05).

Conclusion A decreased albumin level is an independent risk factor for a rapid decline in the kidney function, even within the normal range.

Key words: chronic kidney disease, kidney dysfunction, general population, albumin, Yuport

(Intern Med Advance Publication) (DOI: 10.2169/internalmedicine.4466-20)

Introduction

The number of patients with chronic kidney disease (CKD) has been increasing in most parts of the world, and the disease is estimated to affect 200 million individuals worldwide (1). Furthermore, the increase in the number of patients with CKD is expected to accelerate. CKD creates a large burden and is recognized as an important problem for both individuals and society as a whole. First, CKD is a risk factor for not only end-stage kidney disease (ESKD) but also cardiovascular disease (CVD), which is the main cause of death worldwide (2-5). Second, the worldwide medical expenses associated with hemodialysis due to ESKD is estimated to increase to 1 trillion USD [please check this carefully] within the next 10 years (6). For these reasons, the establishment of an effective measure for CKD prevention is vital; in fact, this is one of the most important issues in pub-
than one checkup during the follow-up period, all of the subjects underwent more than one checkup during the baseline period. During the baseline period, 21,885 people underwent checkups at least once, with a total of 47,995 checkups performed (Fig. 1). If the subjects underwent more than one checkup during the baseline period, the initial checkup data were used. During the follow-up period, 23,547 people underwent checkups at least once for 49,390 checkups. If the subjects underwent more than one checkup during the follow-up period, all of the subjects were included among these 11,000.

In accordance with the Private Information Protection Law, information that might identify subjects was kept private by the center. Informed consent for anonymous participation in epidemiological research was obtained at every checkup.

**Methods**

This was a retrospective cohort study, and we used a dataset derived from the health screening program performed by the Yuport Medical Checkup Center in Tokyo. In this study, we set the 4-year baseline period to be between April 1998 and March 2002 and the 4-year follow-up period to be between April 2002 and March 2006. During the baseline period, 21,885 people underwent checkups at least once, with a total of 47,995 checkups performed (Fig. 1). If the subjects underwent more than one checkup during the baseline period, the initial checkup data were used. During the follow-up period, 23,547 people underwent checkups at least once for 49,390 checkups. If the subjects underwent more than one checkup during the follow-up period, all of the data were used to identify incident diabetes. The follow-up data were merged with the baseline data, yielding 11,129 people who had been examined during both time periods. Of these subjects, 129 with known diabetes at baseline were excluded, leaving 11,000 people. Subjects who were found to have a history of chronic kidney disease were not included among these 11,000.

In the present study, the serum albumin level was determined using the bromocresol green method (reagents supplied by Denka Seiken, Tokyo, Japan) (20). Other laboratory values were measured using the standard laboratory technique. All of the checkup procedures were performed in the same manner, both during the baseline and follow-up periods, including blood measurements. Height and weight were measured to calculate the body mass index (BMI), which was defined as the weight divided by the height squared (kg/m²). Blood pressure was measured by trained nurses using a sphygmomanometer.

**The kidney function**

The kidney function was expressed as an estimated glomerular filtration rate (eGFR) using the CKD Epidemiology Collaboration (CKD-EPI) modified for Japanese (21). The GFR estimated by the coefficient-modified CKD-EPI equation was more closely related to the CVD incidence than that estimated by the Japanese GFR equation (22). The coefficient-modified CKD-EPI equation is as follows:

Estimated GFR (mL/min/1.73 m²) = \(141 \times \min (Cr/κ, 1)^{−1.209} \times \max (Cr/κ, 1)^{−0.293} \times 0.993^{\text{sex}} \times 1.018 \times \text{if (a woman)} \times 0.813 \) (Japanese coefficient)\n
\( (κ: 0.7 \text{ in women and 0.9 in men, α}: −0.329 \text{ in women and } −0.411 \text{ in men}) \)

In general, the kidney function decreases with age: A previous study showed that the rate of GFR decline was 0.36 mL/min/1.73 m²/year on average among 120,727 individuals ≥40 years old (23). Therefore, the clinical kidney disease outcome in this study was assessed as an abnormal annual decline in the kidney function in each participant.

In the present study, an abnormal annual decline in the kidney function was defined as a difference in the eGFR (ΔeGFR) of ≥3 mL/min/1.73 m²/year. This cut-off value for an “abnormal decline,” represents a magnitude of change that is 3 times the rate previously described in studies of normal aging, and this change is known to be associated with clinically deleterious outcomes (24, 25). To ensure the accuracy of the evaluated trend, we also performed a sensitivity analysis in which a ΔeGFR of ≥5 mL/min/1.73 m²/year was regarded as an abnormal decline (26).
Continuous data were expressed as the mean ± standard deviation or median within the 25th and 75th percentiles, and categorical data were expressed as percentages. Baseline characteristics were compared between those who met the criteria for an abnormal decline in the kidney function and those who did not, and independent variables were assessed using the chi-square test in the case of categorical variables and the t-test or Mann-Whitney U test in the case of continuous variables. The analysis for trend was evaluated using the Cochran-Armitage test and Jonckheere-Terpstra test. To assess the relationship between two values, Pearson’s correlation coefficient was employed.

The abnormal decline in the kidney function and odds ratios (ORs) were estimated from the logistic regression model. Multivariable logistic analyses were used to calculate the OR for an abnormal decline in the kidney function after adjusting for the age, sex, BMI, systolic blood pressure (SBP), eGFR at baseline, serum alanine aminotransferase level, serum uric acid level, high-density lipoprotein (HDL) level, HbA1c level, C-reactive protein level, and history of cardiovascular disease (stroke or ischemic heart disease, or both). The inclusion of variables in the models was based on our existing knowledge regarding the risk factors of a kidney function decline. We fit separate multivariable logistic regressions for both the serum albumin level as a continuous variable and categorical data, which were classified as ≤4.3, 4.4-4.6, and ≥4.7 g/dL.

Differences with a P value of <0.05 were considered statistically significant. All statistical analyses were performed using EZR Version 1.33 (Saitama Medical Center, Jichi Medical University, Saitama, Japan), which is a graphical user interface for R (The R Foundation for Statistical Computing, Vienna, Austria). More precisely, it is a modified version of R commander, which is designed to add statistical functions frequently used in biostatistics (27).

Ethics issues

This study was conducted in accordance with the principles of the Declaration of Helsinki. The study was approved by the review board of Teikyo University (approval No. 15-205). The participants’ written informed consent for anonymous participation in epidemiological research was obtained at every evaluation.

Results

The baseline characteristics of the participants according to abnormal decline in the kidney function status are shown in Table 1. Of the participants, 346 had an abnormal decline in the kidney function. Among the patients with an abnormal decline in the kidney function, higher SBP values and lower levels of albumin and HDL-C were observed. The relationship between the baseline serum albumin levels and the change in the eGFR is shown in Fig. 2.

Next, we evaluated the unadjusted and adjusted ORs and 95% confidence intervals (CIs) for an abnormal decline in the kidney function according to the albumin level (Table 2, 3). In the continuous variable evaluation, the albumin levels (per 0.1 g/dL) were negatively associated with the risk of abnormal decline in the kidney function in both the crude (OR=0.89, 95% CI: 0.84-0.93) and adjusted models (OR=0.86, 95% CI: 0.82-0.91). The same trends were also observed in the sensitivity analysis in both the crude (OR=0.88, 95% CI: 0.81-0.97) and adjusted models (OR=0.85, 95% CI: 0.77-0.94).

In the categorical variable evaluation, compared with the participants with albumin levels of ≥4.7 g/dL, the risk of an abnormal decline in the kidney function was significantly higher not only in those with albumin levels of ≤4.3 g/dL but also in those with levels of 4.4-4.6 g/dL (Fig. 3A). This result means that a low serum albumin level, even one still within the normal range, is related to a rapid kidney function decline. The results of the sensitivity analysis, in which a ΔeGFR of ≥5 mL/min/1.73 m²/year was regarded as an abnormal decline in the kidney function, are shown in Fig. 3B. Similar trends were observed.

Discussion

In this retrospective, population-based, cohort study, the relationship between albumin level and decline in the kidney function over time was investigated. A decrease in the albumin level was found to be the primary risk factor for an abnormal decline in the kidney function. More importantly, our study suggests that even when levels were still within the normal range, those with albumin levels of ≤4.6 g/dL had a risk of a decline in the kidney function.

Our study could not clarify why a relatively low but still-within-the-normal-limit level of albumin led to an early decline in the kidney function. A slight decline in serum albumin might reflect some confounding risk factors, such as slight undernutrition (28), slight albuminuria, or profound liver dysfunction. Alternatively, a relatively low level of serum albumin per se caused a rapid decline in the kidney function. A serum albumin, which has the epithet “multifunctional protein” (29), has various functions, including the maintenance of osmotic pressure, buffering of the acid-base balance, supply of amino acid to tissues, binding and transporting of numerous compounds, elastase activity, and antioxidative activity. In fact, the serum albumin level is the most abundant, and thus the most important, antioxidant of the extracellular space (30). We previously reported that the decrease in the serum albumin fraction, which has an antioxidative property, was correlated with kidney dysfunction (31, 32) and that this decrease in the serum albumin fraction was directly related to cardiovascular incidence in the population with advanced CKD (33, 34). Therefore, in theory and in actuality, a low serum albumin level can induce undesirable outcomes, such as mortality (14), cardiovascular incidence (15), and a rapid decline in the kidney
Figure 2. The relationship between the baseline serum albumin level and the yearly decline in the kidney function. A lower serum albumin level was related to a greater decline in the estimated glomerular filtration rate. (A) A weak but significant relationship was observed between the baseline serum albumin level and the yearly decline in the kidney function. (B) The same trend was noted on a trend test (Jonckheere-Terpstra test).
function, as shown in the present study.

Most previous studies considered abnormally low albumin levels as an indicator of malnutrition status for their research (15, 35). However, our study showed that, even within the normal range, albumin levels of ≤4.6 g/dL are associated with a risk of a reduced kidney function. Only a few studies showed that lower albumin levels that were still within the normal range affect the kidney function. Multi-variable analyses in 2,535 subjects 40-69 years old showed that the CKD hazard ratios (95% CI) for the highest and lowest quartiles of serum albumin levels were 0.69 (0.40-1.17) for men and 0.42 (0.28-0.64) for women (36). While these results were similar to ours, the number of subjects was relatively small. To overcome this limitation, in our study, we included almost five times as many subjects as that previous study.

The present study showed that a decreased albumin level was significantly associated with an abnormal decline in the kidney function, and patients with albumin levels of ≤4.6 g/dL had a risk of a decline in the kidney function. This indicated that a slight decrease within the normal range of albumin level might carry a risk of kidney function deterioration. This is consistent with the results of a previous study that reported that a lower albumin level that was still within the normal range was predictive of CKD in women (36). These present and previous findings suggest that the risk of a kidney function decline might increase with decreasing albumin levels, even within the normal range. These findings might support a new therapeutic target from the viewpoint of public health.

Several limitations associated with the present study warrant mention. First, the findings cannot be generalized to other ethnic or age groups, as the study participants might be healthier than the general population with a lower risk of developing medical complications, as the study subjects were participants in a health checkup program. Second, the albumin levels were measured only at baseline; changes in the levels during the follow-up period that might have had an independent effect on the kidney outcome were not evaluated. Third, the eGFR was evaluated only twice; this parameter is known to show day-to-day variations. Fourth, this study did not consider other profound confounders, such as the use of diuretics, smoking history, serum calcium/phosphate levels, cystatin C, brain natriuretic peptide, C-

---

**Table 2. Association between Albumin Level at Baseline and Renal Outcome (ΔeGFR/year ≥3 or Not).**

| Albumin (per 0.1 g/dL) | Unadjusted | Adjusted |
|------------------------|------------|----------|
|                        | N   | OR   | 95%CI | p value | OR   | 95%CI | p value |
| ≤4.3                   | 2,530 | 1.87 | 1.37-2.54 | <0.001 | 2.10 | 1.20-2.93 | <0.001 |
| 4.4-4.6                | 5,427 | 1.41 | 1.06-1.87 | <0.001 | 1.53 | 1.14-2.05 | <0.001 |
| ≥4.75                  | 3,043 | ref  | ref   | ref    | ref  | ref   | ref    |

Adjusted for age, sex, body mass index, systolic blood pressure, eGFR at baseline, serum alanine aminotransferase level, serum uric acid, high-density lipoprotein cholesterol, HbA1c, C reactive protein history of stroke and history of heart disease.

CI: confidence interval, eGFR: Estimated glomerular filtration. ref: reference, OR: odds ratio

---

**Table 3. Sensitivity Analysis: Association between Albumin Level at Baseline and Renal Outcome (ΔeGFR/year ≥5 or Not).**

| Albumin (per 0.1 g/dL) | Unadjusted | Adjusted |
|------------------------|------------|----------|
|                        | N   | OR   | 95%CI | p value | OR   | 95%CI | p value |
| ≤4.3                   | 2,530 | 1.95 | 1.08-3.52 | 0.026 | 2.37 | 1.25-4.42 | 0.002 |
| 4.4-4.6                | 5,427 | 1.47 | 0.85-2.53 | 0.23 | 1.65 | 0.94-2.90 | 0.06 |
| ≥4.75                  | 3,043 | ref  | ref   | ref    | ref  | ref   | ref    |

Adjusted for age, sex, body mass index, systolic blood pressure, eGFR at baseline, serum alanine aminotransferase level, serum uric acid, high-density lipoprotein cholesterol, HbA1c, C reactive protein history of stroke and history of heart disease.

CI: confidence interval, eGFR: Estimated glomerular filtration. ref: reference, OR: odds ratio
reactive protein, cardio-thoracic ratio on chest X-ray, data regarding muscle and fluid volume, and especially data regarding the urinary finding (urinary albumin and protein levels), all which might affect the kidney function and serum albumin level. To overcome such limitations, future prospective studies on these relationships should be conducted to provide more insight.

In conclusion, our study showed that a decreased serum albumin level is an independent risk factor of an abnormal decline in the kidney function in the general population and that a slight decrease in the albumin level, even within the normal range, may be a risk factor of a decline in the kidney function.

The authors state that they have no Conflict of Interest (COI).

Declarations
Funding: The authors received no specific funding for this work.

References
1. Perico N, Remuzzi G. Chronic kidney disease: a research and public health priority. Nephrol Dial Transplant 27 (Suppl 3): iii19-iii 26, 2012.
2. Ritz E. Minor renal dysfunction: an emerging independent cardiovascular risk factor, Heart 89: 963-964, 2003.
3. Ruijbrok LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 38: 1782-1787, 2001.
4. Shoji T, Abe T, Matsuo H, Esga G, Yamasaki Y, Kashihara N, et al. Committee of Renal and Peripheral Arteries, Japan Atherosclerosis Society. Chronic kidney disease, dyslipidemia, and atherosclerosis. J Atheroscler Thromb 19: 299-315, 2012.
5. Nakayama M, Metoki H, Terawaki H, Ohkubo T, Kikuya M, Sato T, et al. Kidney dysfunction as a risk factor for first symptomatic stroke events in a general Japanese population: the Ohasama study. Nephrol Dial Transplant 22: 1910-1915, 2007.
6. Liyanage T, Ninomiya T, Jha V, Neat B, Patrice HM, Okpechi I, et al. Worldwide access to treatment for end-stage kidney disease: a systematic review. Lancet 385: 1975-1982, 2015.
7. Ohkubo Y, Kishikawa H, Araki E, Miyata T, Motoyoshi S, et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract 28: 103-117, 1995.
8. Schaeffer ES, Kurth T, Curhan GC, Glynn RJ, Rexrode KM, Baigent C, et al. Cholesterol and the risk of renal dysfunction in apparently healthy men. J Am Soc Nephrol 14: 2084-2091, 2003.
9. Bakris GL, Williams M, Dworkin L, Elliot WJ, Epstein M, Toto R, et al. Preserving renal function in adults with hypertension and diabetes: a consensus approach. National Kidney Foundation Hypertension and Diabetes Executive Committees Working Group. Am J Kidney Dis 36: 646-661, 2000.
10. Stengel B, Taveral-Carr ME, Powe NR, Eberhardt MS, Brancati FL. Lifestyle factors, obesity and the risk of chronic kidney disease. Epidemiology 14: 479-487, 2003.
11. Perneger TV, Whelton PK, Puddey IB, Klag MJ. Risk of end-stage renal disease associated with alcohol consumption. Am J Epidemiol 150: 1275-1281, 1999.
12. Wakasugi M, Kazama H, Yamamoto S, Kawamura K, Narita I. A combination of healthy lifestyle factors is associated with a decreased incidence of chronic kidney disease: a population-based cohort study. Hypertens Res 36: 328-333, 2013.
13. Yamamoto R, Nagasawa Y, Iwatani H, Shinzawa M, Ohi Y, Teranishi J, et al. Self-reported sleep duration and prediction of proteinuria: a retrospective cohort study. Am J Kidney Dis 59: 343-355, 2012.
14. Gillum RF, Makuc DM. Serum albumin, coronary heart disease, and death. Am Heart J 123: 507-513, 1992.
15. Kuller LH, Eichner JE, Orchard TJ, Grandits GA, McCallum L, Tracy RP. The relation between serum albumin levels and risk of coronary heart disease in the Multiple Risk Factor Intervention

Figure 3. The relationship between the baseline serum albumin level and the renal outcome. A: The main analysis in which the renal outcome was ΔGFR/year ≥3 mL/min/1.73 m²; B: A sensitivity analysis in which the renal outcome was ΔGFR/year ≥5 mL/min/1.73 m². In both analyses, similar trends were observed: Namely, the risk of kidney impairment increased as the serum albumin level decreased, even within the normal range (p-value; <0.001 in A and =0.0249 in B, Cochran-Armitage test). After adjusting for the age, sex, body mass index, systolic blood pressure, eGFR at baseline, serum alanine aminotransferase level, serum uric acid, high-density lipoprotein cholesterol, HbA1c level, C-reactive protein level, and history of cardiovascular disease. CI: confidence interval, eGFR: estimated glomerular filtration
The progression of chronic kidney disease in US adults. Am J Kidney Dis 42: 256-263, 2003.

17. Fried L, Solomon C, Shlipak M, Seliger S, Stehman-Breen C, Bleyer AJ, et al. Inflammatory and prothrombotic markers and the progression of renal disease in elderly individuals. J Am Soc Nephrol 15: 3184-3191, 2004.

18. Bash LD, Erlinger TP, Coresh J, Marsh-Manzi J, Folsom AR, Astor BC. Inflammation, hemostasis, and the risk of chronic kidney disease in middle-aged Japanese individuals: the Circulatory Risk in Communities Study. J Atheroscler Thromb 23: 1089-1098, 2016.

19. Doumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. Clin Chem Acta 258: 21-30, 1997.

20. Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD Epidemiology Collaboration (CKD-EPI) Equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis 56: 32-38, 2010.

21. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, et al. Oxidative stress is enhanced in correlation with renal dysfunction: examination with the redox state of albumin. Kidney Int 66: 1988-1993, 2004.

22. Terawaki H, Nakayama M, Asahi K, Kakamu T, Hayakawa T, Iseki K, et al. Comparison of predictive value for first cardiovascular event between Japanese GFR equation and coefficient-modified CKD-EPI equation. Clin Exp Nephrol 19: 387-394, 2015.

23. Imai E, Horio M, Yamagata K, Iseki K, Hara S, Ura N, et al. Slower decline of glomerular filtration rate in the Japanese general population: a longitudinal 10-year follow-up study. Hypertens Res 31: 433-441, 2008.

24. Rifkin DE, Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168: 2212-2218, 2008.

25. Rifkin DE, Katz R, Chonchol M, Shlipak MG, Sarnak MJ, Fried LF, et al. Blood pressure components and decline in the kidney function in community-living older adults: The Cardiovascular Health Study. Am J Hypertens 26: 1037-1044, 2013.

26. Eriksen BO, Ingebretsen OC. The progression of chronic kidney disease: a 10-year population-based study of the effects of gender and age. Kidney Int 69: 375-382, 2006.

27. Kanda Y. Investigation of the freely available easy-to-use software “EZR” for medical statistics. Bone Marrow Transplant 48: 452-458, 2013.

28. Dickson PW, Howlett GJ, Schreiber G. Metabolism of prealbumin in rats and changes induced by acute inflammation. Eur J Biochem 129: 289-293, 1982.

29. Merlot AM, Kalinowski DS, Richardson DR. Unraveling the mysteries of serum albumin: more than just a serum protein. Front Physiol 5: 299, 2014.

30. Ogasawara Y, Namai T, Togawa T, Ishii K. Formation of albumin dimers induced by exposure to peroxides in human plasma: a possible biomarker for oxidative stress. Biochem Biophys Res Commun 340: 353-358, 2006.

31. Terawaki H, Yoshimura K, Hasegawa T, Matsuyama Y, Negawa T, Yamada K, et al. Serum albumin and high-sensitivity C-reactive protein are independent risk factors of chronic kidney disease in middle-aged Japanese individuals: the Circulatory Risk in Communities Study. J Atheroscler Thromb 23: 465-471, 2010.

32. Terawaki H, Matsuyama Y, Matsuo N, Ogura M, Mitome J, Hamaguchi A, et al. A lower level of reduced albumin induces severe cardiovascular incidence in hemodialysis patients. Ther Apher Dial 14: 629-635, 2012.

33. Li Q, Zhao M, Du J, Wang X. Outcomes of renal function in elderly patients with acute kidney injury. Clin Interv Aging 12: 153-160, 2017.

34. Kubo S, Kitamura A, Imano H, Cui R, Yamagishi K, Umesawa M, et al. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Epidemiol 134: 1266-1277, 1991.

35. Erlinger TP, Tarver-Carr ME, Powe NR, Appel LJ, Coresh J, Eberhardt MS, et al. Leukocytosis, hypoalbuminemia, and the risk for chronic kidney disease in US adults. Am J Kidney Dis 42: 256-263, 2003.

36. Shlipak MG, Katz R, Fried LF, Siscovick D, Chonchol M, et al. Rapid kidney function decline and mortality risk in older adults. Arch Intern Med 168: 2212-2218, 2008.